Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction

Abstract Cancer therapeutics-related cardiac dysfunction (CTRCD) has emerged as a major cause of morbidity and mortality in cancer survivors. Effective clinical management of CTRCD is impeded by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular research 2023-05, Vol.119 (3), p.710-728
Main Authors: Tonry, Claire, Russell-Hallinan, Adam, McCune, Claire, Collier, Patrick, Harbinson, Mark, Dixon, Lana, Watson, Chris J
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Biomarkers
Cardiotoxicity - drug therapy
Echocardiography
Heart Diseases - chemically induced
Heart Diseases - diagnosis
Heart Diseases - therapy
Humans
Neoplasms - diagnosis
Neoplasms - drug therapy
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Cancer therapeutics-related cardiac dysfunction (CTRCD) has emerged as a major cause of morbidity and mortality in cancer survivors. Effective clinical management of CTRCD is impeded by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially address this need as they are often indicative of cardiac stress before cardiac damage can be detected clinically. A growing understanding of the underlying physiological mechanisms for CTRCD has inspired research efforts to identify novel pathophysiologically relevant biomarkers that may also guide development of cardio-protective therapeutic approaches. The purpose of this review is to evaluate current circulating biomarkers of cardiac stress and their potential role in diagnosis and management of CTRCD. We also discuss some emerging avenues for CTRCD-focused biomarker investigations. Graphical Abstract Graphical abstract Circulating biomarkers for chemotherapeutics-related cardiac dysfunction. Examples of chemotherapeutic reagents that affect cardiac function are shown (A). Chemotherapeutic reagents exert toxic effects on the heart via various mechanisms (B). Novel technologies are being utilized to investigate biologically relevant markers of cardiac dysfunction in the circulation (C).
ISSN:0008-6363
1755-3245
DOI:10.1093/cvr/cvac087